These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 21585248)
1. Ixabepilone for the treatment of breast cancer. Alvarez RH; Valero V; Hortobagyi GN Ann Med; 2011; 43(6):477-86. PubMed ID: 21585248 [TBL] [Abstract][Full Text] [Related]
2. Ixabepilone, a new treatment option for metastatic breast cancer. Toppmeyer DL; Goodin S Am J Clin Oncol; 2010 Oct; 33(5):516-21. PubMed ID: 20023567 [TBL] [Abstract][Full Text] [Related]
3. Activity of ixabepilone in patients with metastatic breast cancer with primary resistance to taxanes. Yardley DA Clin Breast Cancer; 2008 Dec; 8(6):487-92. PubMed ID: 19073502 [TBL] [Abstract][Full Text] [Related]
5. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. Thomas ES J Clin Oncol; 2008 May; 26(13):2223. PubMed ID: 18445853 [No Abstract] [Full Text] [Related]
6. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. Boehnke Michaud L J Oncol Pharm Pract; 2009 Jun; 15(2):95-106. PubMed ID: 19171553 [TBL] [Abstract][Full Text] [Related]
7. Ixabepilone: clinical role in metastatic breast cancer. Denduluri N; Swain S Clin Breast Cancer; 2011 Jun; 11(3):139-45. PubMed ID: 21665133 [TBL] [Abstract][Full Text] [Related]
8. Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms. Vahdat L Oncologist; 2008 Mar; 13(3):214-21. PubMed ID: 18378531 [TBL] [Abstract][Full Text] [Related]
10. Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: a pooled subset analysis of two phase III studies. Jassem J; Fein L; Karwal M; Campone M; Peck R; Poulart V; Vahdat L Breast; 2012 Feb; 21(1):89-94. PubMed ID: 21937232 [TBL] [Abstract][Full Text] [Related]
11. Application of epothilones in breast cancer therapy. Cianfrocca M Curr Opin Oncol; 2008 Nov; 20(6):634-8. PubMed ID: 18841044 [TBL] [Abstract][Full Text] [Related]
12. Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. Lechleider RJ; Kaminskas E; Jiang X; Aziz R; Bullock J; Kasliwal R; Harapanhalli R; Pope S; Sridhara R; Leighton J; Booth B; Dagher R; Justice R; Pazdur R Clin Cancer Res; 2008 Jul; 14(14):4378-84. PubMed ID: 18628451 [TBL] [Abstract][Full Text] [Related]
13. Advances in breast cancer treatment: the emerging role of ixabepilone. Frye DK Expert Rev Anticancer Ther; 2010 Jan; 10(1):23-32. PubMed ID: 20014882 [TBL] [Abstract][Full Text] [Related]
14. Budget impact analysis of ixabepilone used according to FDA approved labeling in treatment-resistant metastatic breast cancer. Ho J; Zhang L; Todorova L; Whillans F; Corey-Lisle P; Yuan Y J Manag Care Pharm; 2009; 15(6):467-75. PubMed ID: 19610679 [TBL] [Abstract][Full Text] [Related]
15. Lapatinib and ixabepilone for the treatment of metastatic breast cancer. Halterman PA Pharmacotherapy; 2008 Oct; 28(10):1255-66. PubMed ID: 18823221 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Perez EA; Lerzo G; Pivot X; Thomas E; Vahdat L; Bosserman L; Viens P; Cai C; Mullaney B; Peck R; Hortobagyi GN J Clin Oncol; 2007 Aug; 25(23):3407-14. PubMed ID: 17606974 [TBL] [Abstract][Full Text] [Related]
17. Q-TWiST analysis of ixabepilone in combination with capecitabine on quality of life in patients with metastatic breast cancer. Corey-Lisle PK; Peck R; Mukhopadhyay P; Orsini L; Safikhani S; Bell JA; Hortobagyi G; Roche H; Conte P; Revicki DA Cancer; 2012 Jan; 118(2):461-8. PubMed ID: 21598243 [TBL] [Abstract][Full Text] [Related]
18. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Perez EA Breast Cancer Res Treat; 2009 Mar; 114(2):195-201. PubMed ID: 18443902 [TBL] [Abstract][Full Text] [Related]
19. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/resistant and taxane-resistant metastatic breast cancer. Bunnell C; Vahdat L; Schwartzberg L; Gralow J; Klimovsky J; Poulart V; Peck R; Thomas E Clin Breast Cancer; 2008 Jun; 8(3):234-41. PubMed ID: 18650153 [TBL] [Abstract][Full Text] [Related]
20. Ixabepilone: a novel microtubule inhibitor for the treatment of locally advanced or metastatic breast cancer. Steinberg M Clin Ther; 2008 Sep; 30(9):1590-617. PubMed ID: 18840366 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]